Isomorphic Labs Raises $2.1B Series B to Accelerate AI Drug Discovery

A $2.1 Billion Bet on AI Drug Design

Isomorphic Labs announced on May 12, 2026 that it has raised $2.1 billion in Series B funding, led by Thrive Capital. The round brings in a broad coalition of investors: existing backers Alphabet and GV, alongside new participants MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.

From AlphaFold to Drug Design

Founded in 2021 by DeepMind co-founder Demis Hassabis, Isomorphic Labs was built on the premise that AI can fundamentally reimagine drug discovery. Its core technology, the Isomorphic Drug Design Engine (IsoDDE), extends beyond protein structure prediction into the active design and optimization of drug candidates across multiple therapeutic areas and modalities.

Where the Capital Goes

The company plans to deploy the funding toward three priorities:

• Advancing the IsoDDE platform
• Scaling the business globally
• Progressing its drug candidate pipeline across therapeutic areas

The Bigger Picture

This is one of the largest single rounds in AI healthcare to date. If AlphaFold changed how scientists understand proteins, Isomorphic Labs is betting that AI can now change how drugs are actually designed — and $2.1 billion suggests investors believe the timeline is shorter than most expected.